Nasal spray bromocriptine: Effects on serum prolactin in puerperal women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 75, Issue 8, 1996, Pages 730-733

  Cicinelli, Ettore ^a,b   Petruzzi, Donatina ^a   Ragno, Gaetano ^a   Schönauer, Luca Maria ^a   Ruccia, Carmela ^a   Matteo, Giuseppina ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NONE   (Italy)

Author keywords

Bromocriptine; Hyperprolactinemia; Nasal route; Nasal spray

Indexed keywords

BROMOCRIPTINE MESILATE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPROLACTINEMIA; INTRANASAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; TIME;

EID: 0029985132     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016349609065736     Document Type: Article

References (8)

1. Cuellar FG. Bromocriptine mesylate (Parlodel) in the management of amenorrhea-galactorrhea associated with hyperprolactinemia. Obstet Gynecol 1980; 55: 278-84.
2. Friesen H, Tolis G. Use of bromocriptine in the galactorrhea-amenorrhea syndromes. The Canadian Cooperative Study. Clin Endocrinol (Oxf) 1977; 6 (suppl): 915.
3. Katz E, Schran HF, Adashi EY. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstet Gynecol 1989; 73: 517-20.
4. Gopinath PG, Gopinath RD, Anad Kumar TC. Target site of intranasally sprayed substances and their transport across the nasal mucosa: a new insight into intranasal route of drug delivery. Curr Rher Res 1978; 23: 596-607.
5. Aellig WH, Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol Res 1977; 15: 106-12.
6. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl J Med 1994; 331: 904-9.
7. Rolland R. On Parlodel® LAR and optimal treatment of hyperprolactinemia. In Pepperel RJ, ed. New aspects of dopamine agonist therapy in menstrual cycle disorders and infertility. Carsterton Hall, Carnforth, Lancs UK: The Parthenon Publishing Group 1990; 33-46.
8. Hussain MA, Rakestraw D, Rowe S, Aungst B. Nasal administration of a cognition enhancer provides improved bioavailability but not enhanced brain delivery. J Pharm Sci 1990; 79: 771-2.